Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group
Keyword(s):
Phase 3
◽
Keyword(s):
Keyword(s):
Keyword(s):